Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022


BOSTON and ATLANTA, Aug. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will report financial results for the second quarter ended June 30, 2022 on Friday, August 12, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Monday, August 15, 2022 to provide a corporate update and review the financial results.

The conference call can be accessed by dialing 844-825-9789 (United States) or 412-317-5180 (International) with the conference code 10169366. A live webcast may be accessed using the link here, or by visiting the investors section of the Company's website at www.inhibikase.com. After the live webcast, the event will be archived on Inhibikase's website for approximately 90 days after the call.

About Inhibikase (www.inhibikase.com)                                                                                             

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMPtm medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use TwitterFacebookLinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Contacts:

Company Contact: 
Milton H. Werner, Ph.D. 
President & CEO 
678-392-3419 
[email protected]

Investor Relations:
Alex Lobo
SternIR, Inc.
[email protected]

SOURCE Inhibikase Therapeutics, Inc.


These press releases may also interest you

at 23:43
TOKEN2049, Asia's premier crypto conference, announced a record-breaking 7,000+ attendees, 2,000+ global companies, and 250+ sponsors for its Singapore debut, making it the industry's largest and most well-attended event in years. As the flagship...

at 23:28
Guided by the principle of "less effort, more living", CHiQ aims to improve quality of life for its users with smart and dependable products that handle essential tasks intelligently and with ease, whereby customers can lead happier and more relaxed...

at 22:45
TOKEN2049, Asia's premier crypto conference, announced a record-breaking 7,000+ attendees, 2,000+ global companies, and 250+ sponsors for its Singapore debut, making it the industry's largest and most well-attended event in years. As the flagship...

at 22:16
Guided by the principle of "less effort, more living", CHiQ aims to improve quality of life for its users with smart and dependable products that handle essential tasks intelligently and with ease, whereby customers can lead happier and more relaxed...

at 21:30
Exicom, the leading EV charger and Li-ion battery manufacturer today said it has emerged as the largest EV charging brand in Malaysia with 40 per cent share in the country....

at 21:30
The global active optical cable market is prognosticated to reach a value of US$ 15.21 Bn by the end of 2031,...



News published on 8 august 2022 at 08:30 and distributed by: